CERECOR INC. (NASDAQ:CERC) Files An 8-K Other Events

CERECOR INC. (NASDAQ:CERC) Files An 8-K Other Events
Item 8.01. Other Events.

As previously disclosed, on October 10, 2019, Cerecor Inc. (the “Company”) entered into, and subsequently closed on November 1, 2019, an asset purchase agreement with Aytu BioScience, Inc. to sell the Company’s rights, title and interest in, assets relating to its Pediatric Portfolio, namely Aciphex® Sprinkle™, Cefaclor for Oral Suspension, Karbinal™ ER, Flexichamber™, Poly-Vi-Flor® and Tri-Vi-Flor™, as well as the corresponding commercial infrastructure consisting of the right to offer employment to Cerecor’s sales force and the assignment of supporting commercial contracts (collectively, the “Aytu Transaction”).
We are issuing this Current Report on Form 8-K to voluntarily disclose the attached Exhibit 99.1, which is incorporated herein by reference, and contains unaudited pro forma condensed combined financial statements that illustrate the effects directly attributable to the Aytu Transaction.
The unaudited pro forma condensed combined financial statements contained in this Current Report on Form 8-K should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2018, and subsequent filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.> Description
Cerecor Inc. Exhibit
EX-99.1 2 ex-991proformaaytudivestit.htm EXHIBIT 99.1 Exhibit Exhibit 99.1UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATIONThe following unaudited pro forma condensed combined financial statements are based upon the historical consolidated statements of Cerecor Inc. (\”Cerecor\” or the \”Company\”),…
To view the full exhibit click here

Story continues below

About CERECOR INC. (NASDAQ:CERC)

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson’s disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.

An ad to help with our costs